NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Scynexis, Inc. SCYX
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$20.6M
▲ 449.9% vs FY2024
EPS · FY25
$-0.17
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-16.5%
Net margin · FY25
-41.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 20.6M
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 42 cents on every revenue dollar this year.
Per share
USD -0.17
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-16.5%
Return on equity, FY2025
ROE
Operating margin-78.0%
Net margin-41.8%
Return on assets-11.5%
Each USD of equity lost 16 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+59.4%
+55.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+121.4%
Change, 10 years—
The share count grew 121% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 59.0M
total assets, end of FY2025
Total assetsUSD 59.0M
EquityUSD 49.4M
CashUSD 21.3M
Current ratio7.04×
Equity funds 84% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.0
−0.0
0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.17
−0.44
1.39
−1.47
−1.25
·
·
·
·
−1.58
−2.68
−2.69
−139.47
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−16.5
−33.3
176.0
−282.3
−102.7
−309.6
−243.5
−47.4
−89.1
−78.1
−86.6
·
·
Shares out B
0.04
0.04
0.04
0.03
0.03
0.02
0.01
0.05
0.03
0.02
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed